Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to Europe The first...

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety...